Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Sprakes

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Arthritis Research & Therapy|December 19, 2008
NOD-like receptors and inflammationRebeccah J Mathews, Michael B Sprakes, Michael F McDermott
Journal of Crohn'S & Colitis|February 14, 2012
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experienceMichael B Sprakes, Alexander C Ford, Lisa Warren, et al.
Journal of Crohn'S & Colitis|June 21, 2011
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experienceMichael B Sprakes, P John Hamlin, Lisa Warren, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Arthritis Research & Therapy|December 19, 2008
NOD-like receptors and inflammationRebeccah J Mathews, Michael B Sprakes, Michael F McDermott
Journal of Crohn'S & Colitis|February 14, 2012
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experienceMichael B Sprakes, Alexander C Ford, Lisa Warren, et al.
Journal of Crohn'S & Colitis|June 21, 2011
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experienceMichael B Sprakes, P John Hamlin, Lisa Warren, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 1